The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index; 4 of the 15 sources its claims cite were checked for support.
SSRI and SNRI withdrawal symptoms reported on an internet forum
Open accessAbstract
BACKGROUND: Antidepressant withdrawal symptoms are well-recognised, but their potential duration remains uncertain. OBJECTIVE: We aimed to describe the characteristics of withdrawal associated with two popular classes of antidepressants, including duration. METHODS: We analysed the content of a sample of posts on an antidepressant withdrawal website. We compared the characteristics of withdrawal associated with SSRIs and SNRIs, including time of onset, duration and nature of symptoms. RESULTS: 110 posts about SSRI withdrawal, and 63 concerning SNRI withdrawal, were analysed. The mean duration of withdrawal symptoms was significantly longer with SSRIs than SNRIs: 90.5 weeks (standard deviation, SD, 150.0) and 50.8 weeks (SD 76.0) respectively; p = 0.043). Neurological symptoms, such as ‘brain zaps,’ were more common among SNRI users ( p = 0.023). Psychosexual/genitourinary symptoms may be more common among SSRI users ( p = 0.054). LIMITATIONS: The website aims to help people with antidepressant withdrawal, and is therefore likely to attract people who have difficulties. Length of prior use of antidepressants was long, with a mean of 252.2 weeks (SD 250.8). CONCLUSIONS: People accessing antidepressant withdrawal websites report experiencing protracted withdrawal symptoms. There are some differences in the characteristics of withdrawal associated with different classes of antidepressants.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 8 Not checked · 30 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, other research suggests that internet data can be used to provide reliable accounts of users' experiences of drug-induced adverse effects that are consistent with academic and professional literature [15].”
What the sources say
- Partly supportedcites [15] sourceExperimental — accuracy not yet measured
The Discussion’s Principal Results report that online consumer reviews and professional descriptions identified many of the same effects for two psychotropic drugs. But the Limitations section says the authenticity and credibility of individual posts are unknown and that this correspondence only may add validity. The paper does not establish that the accounts are reliable or compare them directly with academic literature. (LLM, conf=0.84)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Common symptoms following SSRI withdrawal include dizziness, nausea, fatigue, anxiety, headache, electric shock-like symptoms, sweating, insomnia and nightmares [6].”
What the sources say
- Supportedcites [6] source
Table 1 in the Discussion lists all nine symptoms as signs of SSRI withdrawal. The Introduction also names most of them in its description of withdrawal-symptom criteria. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“There is now clear evidence that a variety of symptoms can result from the discontinuation of all antidepressant classes [4].”
What the sources say
- Supportedcites [4] source
The Abstract (p. 447) states that discontinuation (withdrawal) symptoms 'occur with all classes of antidepressant, including the TCAs, monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors (SNRIs) and miscellaneous others such as mirtazapine', backed by the authors' PubMed review identifying reports with 25 antidepressants (Box 1 lists agents across all five groupings). The 'Nature of symptoms' section adds that these symptoms 'are diverse and differ between antidepressant classes', with over 50 different symptoms catalogued in SSRI case reports, and the symptom checklists in the paper enumerate sensory, somatic, affective, gastrointestinal and sleep domains. Both halves of the claim — variety of symptoms and all antidepressant classes — are therefore stated in our copy. (LLM, conf=0.92)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Neurological symptoms, such as 'brain zaps,' were more common among SNRI users (p=0.023).”
- Also stated in: § Results · plain
“Neurological effects were significantly more common among people who had withdrawn from SNRIs.”
plainstates an associationn = 174 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Psychosexual/genitourinary symptoms may be more common among SSRI users (p=0.054).”
- Also stated in: § Results · hedged
“There was a trend towards sexual and genitourinary effects being more frequent in people withdrawing from SSRIs; however, this difference did not reach statistical significance.”
hedgedstates an associationn = 174 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · hedged
8 more claims
Create a free account to see all 42 claims and to verify the 11 references still open.
- Probably not a substantial claim. 14
- It may state two separate claims as one. 17
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Withdrawal symptoms typically emerged within a few days of dose reduction or cessation, but delayed onset also occurred, sometimes weeks or even months after treatment discontinuation (Stockmann et al., 2018).”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Stockmann et al., 2018
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“there is evidence to suggest that patients who have withdrawn from antidepressants can experience symptoms that last for months, and, sometimes, for years.5,15,16”
The cited source says what the claim attributes to it.
In the citing paper
“In contrast, the length of prior treatment was not correlated with the duration of withdrawal symptoms”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Stockmann et al., 2018
The cited source says what the claim attributes to it.
In the citing paper
“and neither length of taper nor duration of previous treatment correlated with time to onset of withdrawal symptoms (Stockmann et al., 2018).”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Stockmann et al., 2018
The cited source says what the claim attributes to it.
In the citing paper
“with an average duration of withdrawal symptoms of 90.5 weeks for SSRI and 50.8 weeks for SNRI in the other study (Stockmann et al., 2018).”
From Post-acute withdrawal syndrome (PAWS) after stopping antidepressants: a systematic review with meta-narrative synthesis (2025) · cites this paper as Stockmann et al., 2018
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Method
“Differences between groups were explored using non-parametric tests, due to the skewed nature of distributions.”
§ Conclusion
“The mean duration of withdrawal symptoms in the SSRI group was 90.5 weeks (SD 150.0; median 34.0, IQR 8.0-104.0;N=97), and in the SNRI group 50.8 weeks (SD 76.0; median 28.0, IQR 4.5-62.8;N=40); t=2.05, p=0.043.”
Citations
Cites
Trends in Prescription Drug Use Among Adults in the United States From 1999-2012
Kantor, E. D., Rehm, C. D., Haas, J. S., Chan, A. T., & Giovannucci, E. L. (2015) · JAMA · doi:10.1001/jama.2015.13766 · Cited by 1,219
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436 · cited 2×
“Common symptoms following SSRI withdrawal include dizziness, nausea, fatigue, anxiety, headache, electric shock-like symptoms, sweating, insomnia and nightmares [6].”
InfluentialMoore, M., Yuen, H. M., Dunn, N., Mullee, M. A., Maskell, J., & Kendrick, T. (2009) · BMJ · doi:10.1136/bmj.b3999 · Cited by 287
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Recognising and managing antidepressant discontinuation symptoms
Haddad, P. M., & Anderson, I. M. (2007) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.105.001966 · Cited by 109
Kendrick, T., Stuart, B. L., Newell, C., Geraghty, A. W. A., & Moore, M. V. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.06.052 · Cited by 68
Hughes, S., & Cohen, D. (2011) · Journal of Medical Internet Research · doi:10.2196/jmir.1716 · Cited by 57
Belaise, C., Gatti, A., Chouinard, V.-A., & Chouinard, G. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000341178 · Cited by 45
Attacks on antidepressants: signs of deep-seated stigma?
Nutt, D., Goodwin, G. M., Bhugra, D., Fazel, S., & Lawrie, S. M. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70232-9 · Cited by 31
Kuehn, B. M. (2011) · JAMA · doi:10.1001/jama.2011.1697 · Cited by 2
Cited by
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157
Guy, A., Brown, M., Lewis, S., & Horowitz, M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967183 · Cited by 77
Metadata
- Authors
- Stockmann, T., Odegbaro, D., Timimi, S., & Moncrieff, J.
- Affiliations
- North East London NHS Foundation Trust (GB)
- Northampton Healthcare NHS Foundation Trust, Northampton, UK
- University of Lincoln (GB)
- University College London (GB)
- Venue
- International Journal of Risk & Safety in Medicine
- Publisher
- SAGE Publications
- Published
- 2018-08
- Volume
- 29
- Issue
- 3-4
- Pages
- 175-180
- ISSN
- 0924-6479 (ISSN-L)
- 1878-6847
- OpenAlex
- W2799697481
- Semantic Scholar
- 167374fb74e7d230268617cf9a384744c2998242
- Cited by
- 54
- References
- 11
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 6 · 2023: 4 · 2022: 4 · 2021: 7 · 2020: 6 · 2019: 11 · 2018: 1
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- International Journal of Risk & Safety in Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- antidepressant withdrawal symptoms, selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, online forums, neurological symptoms, genitourinary symptoms, antidepressant discontinuation
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Antidepressive Agents, Humans, Retrospective Studies, Substance Withdrawal Syndrome, Time Factors, Internet, Self Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SSRI and SNRI withdrawal symptoms reported on an internet forum. https://app.cochat.ai/papers/10.3233/jrs-180018
- The paper
- Stockmann, T., Odegbaro, D., Timimi, S., & Moncrieff, J. (2018). SSRI and SNRI withdrawal symptoms reported on an internet forum. International Journal of Risk & Safety in Medicine. https://doi.org/10.3233/jrs-180018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.